Trial Profile
ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms Compare Absorb
- 01 Sep 2020 Results of pooled analysis from COMPARE-ABSORB and AIDA presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 01 Sep 2020 Results of pooled analysis from COMPARE-ABSORB and AIDA presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 13 Aug 2018 Planned primary completion date changed from 1 Mar 2018 to 28 Aug 2018.